FAQ

The 4th Obesity & Weight Loss Drug Development Summit is a leading, industry-led conference dedicated to advancing next-generation obesity therapeutics. Taking place July 14–16, 2026 in Boston, it brings together experts across pharma, biotech, and solution providers to address the most pressing challenges in obesity drug development, from novel mechanisms and clinical strategy to long-term patient outcomes.

Designed to move beyond headline clinical data, the summit focuses on real-world application, strategic insights, and collaborative problem-solving to accelerate the development of durable, high-quality obesity treatments.

The summit is designed for senior professionals and scientists working in obesity and metabolic drug development, including:

• Pharma and biotech leaders (C-level, VP, Director, Head)
• R&D, preclinical, clinical, and translational scientists
• Business development and partnership teams
• CROs, biomarker, and real-world evidence providers

It is particularly valuable for those working on obesity, GLP-1, metabolic, or cardiometabolic therapies

Attending the summit allows you to:

• Gain practical insights into clinical, regulatory, and commercial challenges
• Learn how to differentiate next-generation therapies beyond GLP-1s
• Connect with senior decision-makers across pharma and biotech
• Accelerate your pipeline through partnerships and collaboration opportunities

The event is focused on delivering actionable takeaways, not just theoretical insights or data presentations.

The agenda focuses on the most critical topics in obesity drug development, including:

• Next-generation therapies beyond GLP-1 (amylins, siRNA, small molecules)
• Clinical trial design and regulatory strategy
• Muscle preservation and “quality of weight loss”
• Long-term maintenance and preventing weight regain
• Precision medicine, biomarkers, and patient stratification

This ensures coverage across the full drug development lifecycle.

No. While GLP-1 therapies are discussed, the summit goes far beyond them.

It focuses heavily on next-generation and non-GLP-1 approaches, including:

• Combination and multi-agonist therapies
• Novel biological pathways
• Targeted and precision-based treatments

This makes it a future-focused event for companies looking to differentiate in a competitive market.

The summit attracts a highly curated audience of senior decision-makers, including representatives from:

• Leading pharma companies (e.g., Novo Nordisk, Eli Lilly, Roche)
• Innovative biotech companies developing next-generation therapies
• CROs and specialist solution providers

The audience is intentionally targeted and high-quality, enabling meaningful networking and collaboration.

This summit stands out because it is:

• Industry-led and drug-development focused (not clinician or academic-led)
• Disease-focused, covering all obesity modalities—not just GLP-1
• Designed for small, high-value networking, not large-scale crowds
• Focused on practical insights, including regulatory, clinical, and partnering challenges

It prioritises real-world application and strategic discussion, rather than just presenting new data.

The summit will take place:

• July 14–16, 2026
• Boston, Massachusetts, USA

It includes two pre-conference workshops and two main conference days.

By attending, you will:

• Stay ahead of rapid industry developments and emerging therapies
• Learn how to overcome drug development and regulatory challenges
• Gain competitive intelligence on the evolving obesity landscape
• Build relationships with partners, investors, and collaborators

The summit is designed to help you accelerate decision-making and development timelines.

You can register directly via the event website.

Registration options include:

• Conference-only passes
• Conference + workshop packages
• Early-bird discounts (available for a limited time)
• Group discounts for companies bringing 2 or more delegates

Pricing varies depending on your organisation type (e.g., drug developer, academic, or solution provider).